Cargando…
Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate
The endocannabinoid system (ECS), a signalling network with immunomodulatory properties, is a potential therapeutic target in multiple sclerosis (MS). Dimethyl fumarate (DMF) is an approved drug for MS whose mechanism of action has not been fully elucidated; the possibility exists that its therapeut...
Autores principales: | Sánchez-Sanz, Alicia, Posada-Ayala, María, Sabín-Muñoz, Julia, Fernández-Miranda, Ismael, Aladro-Benito, Yolanda, Álvarez-Lafuente, Roberto, Royuela, Ana, García-Hernández, Ruth, la Fuente, Ofir Rodríguez-De, Romero, Julián, García-Merino, Antonio, Sánchez-López, Antonio José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700785/ https://www.ncbi.nlm.nih.gov/pubmed/36434122 http://dx.doi.org/10.1038/s41598-022-21807-y |
Ejemplares similares
-
Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients
por: Sánchez-Sanz, Alicia, et al.
Publicado: (2023) -
Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS
por: Gafson, Arie R., et al.
Publicado: (2018) -
Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017) -
Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016) -
A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles
por: García-Fernández, Francisco Javier, et al.
Publicado: (2021)